The subcutaneous implantable cardioverter–defibrillator (ICD) is associated with fewer lead-related complications than a transvenous ICD; however, the subcutaneous ICD cannot provide bradycardia and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A leadless pacing-defibrillator system was safe and met ...

EBR Systems, Inc., developer of the world’s only leadless left ventricular endocardial pacing (LVEP) system for heart failure, today announced its participation in the Heart Rhythm 2026 conference, ...

Cardiac physiologic pacing, also known as cardiac resynchronization therapy, is indicated in patients with heart failure, reduced left ventricular ejection fraction (LVEF) of 50% or less, and either a ...

First-of-its-kind Aurora EV-ICD™ system offers single device, single procedure with lead placed outside of heart and veins FDA approval of the Medtronic Aurora EV-ICD system includes the system's ...

Left bundle branch area pacing was found to be an effective and practical strategy for cardiac resynchronisation, according to a Late-Breaking Science presentation at EHRA 2026,1 the annual congress ...

NEW ORLEANS -- An investigational extravascular implantable cardioverter-defibrillator (ICD) continues to demonstrate it can appropriately shock patients and prevent sudden cardiac death, extended ...

A new type of extravascular implantable cardioverter-defibrillator (ICD) using a lead (thin wire) placed behind the sternum met safety and effectiveness goals for participants in a premarket global ...

Though the PRAETORIAN group was technically unable to prove that 8 years was enough to give a subcutaneous implantable cardioverter-defibrillator (ICD) an edge in safety, complication rates helped ...

In 2022, the field of heart rhythms saw new research into innovative pacing technologies, a long-awaited guideline update, and new drug therapy options emerging for patients with arrhythmias.